CLYMClimb Bio, Inc.

$522M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

-$8M

EPS (Diluted)

$-0.29

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$135M

Total Liabilities

$6M

Stockholders' Equity

$129M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$10M	-$11M	+10.7%
Net Income	-$8M	-$11M	+26.4%

CLYM Q4 2022 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena